Propanc Biopharma, Inc. (PPCB): debt financing — Propanc Biopharma issues $150K convertible note to One44 Capital at 10% interest, 60% conversion discount

Propanc Biopharma, Inc.

Principal $150K; purchase price $135K (15% OID); 10% interest; maturity Dec 8, 2024.
Convertible at 60% of lowest trading price over prior 15 days; subject to 4.99% beneficial ownership cap.
Issued under Regulation D private placement; net proceeds for working capital.
Prepayment option: 115% within 60 days, 130% 61-120 days, 140% 121-180 days; none after 180 days.

Key facts

Extracted from this filing and checked against the source text.

Debt Financings SEC 8-K Item 2.03/2.04 confidence 0.9

Propanc Biopharma, Inc. incurred convertible notes of $150,000 with Investor at ten percent (10%) per annum maturing December 8, 2024.

Instrument: convertible notes
Principal: $150,000
Counterparty: Investor
Rate: ten percent (10%) per annum
Maturity: December 8, 2024
Event: incurrence

Exact text from the filing

entered into and closed a securities purchase agreement (the “Purchase Agreement”) with an investor (the “Investor”), pursuant to which the Investor agreed to purchase a convertible promissory note from the Company in the aggregate principal amount of $150,000

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Propanc Biopharma, Inc. entered into Purchase Agreement with an investor valued at principal amount of $150,000 (effective 2023-12-11).

Action: entry
Agreement: equity purchase
Counterparty: an investor
Value: principal amount of $150,000
Effective: 2023-12-11

Exact text from the filing

Effective December 11, 2023, Propanc Biopharma, Inc. (the “Company”) entered into and closed a securities purchase agreement (the “Purchase Agreement”) with an investor (the “Investor”), pursuant to which the Investor agreed to purchase a convertible promissory note from the Company in the aggregate principal amount of $150,000 (the “Note”), for a purchase price of $135,000.

View on SEC.gov

10 debt financings filed in the last 30 days. Browse all debt financings →

Propanc Biopharma, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-23-045035

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.